InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,313.92
(
0.13%
)
US TECH 100
18,291.20
(
0.34%
)
Dow Jones
39,390.27
(
-0.71%
)
Brent Oil
81.48
(
-0.06%
)
Bitcoin
68,129.19
(
-1.40%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 186

Saturday, 06/02/2018 7:11:03 PM

Saturday, June 02, 2018 7:11:03 PM

Post# of 438
ABEO is a rare disease gene platform company that addresses lyposomal storage disorders

Lyposmomal storage disorders are caused by deficiencies of enzymmes needed for stepwise breakdown of glycoaminoglycans (GAGs)

GAG build-up are assoicated with several rare diseases. Consequently, ABEO has a substantial pipeline.

5/18, ABEO reported Ph2 results against San Filippo Syndrome that showed stellar efficacy over 18 months.

The lead program is in Ph3 against Epidermolysis.

Cash runway is into H-1 2020.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up